Plain-English translation of NCT07488975 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called Akkermansia muciniphila — a beneficial bacteria that has been heat-treated and made into a capsule — to see if it can help reduce fat buildup in the liver. Researchers want to know if this treatment is safe and whether it actually works to improve fatty liver disease, which affects people whose livers accumulate too much fat due to metabolic problems.
Fatty liver disease is a growing health problem with no cure, and current treatment options are limited. This medication is being tested because early research suggests that beneficial bacteria in the gut might help reduce liver fat and improve overall liver health.
You likely qualify if…
You likely don't qualify if…
You will take one capsule of the medication (or placebo) by mouth each day for 120 days — about 4 months. You'll be randomly assigned to receive either a low, medium, or high dose of the treatment, or a placebo (inactive pill), so neither you nor the researchers will know which one you're taking. Throughout the study, you'll have visits to check your health, have blood tests, and have ultrasound scans to see if your liver is improving.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Taiwan